{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:15:27Z","timestamp":1790738127475,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.tranon.2024.102140","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T06:24:46Z","timestamp":1728109486000},"page":"102140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-0354","authenticated-orcid":false,"given":"Sumit","family":"Mallick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1619-3778","authenticated-orcid":false,"given":"Asim K","family":"Duttaroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9189-7962","authenticated-orcid":false,"given":"Suman","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2024.102140_bib0001","article-title":"Phase II study of taselisib in PIK3CA-mutated solid tumors other than breast and squamous lung cancer: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol I","volume":"6","author":"Krop","year":"2022","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0002","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0003","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.25122\/jml-2021-0108","article-title":"Triple-negative breast cancer: current treatment strategies and factors of negative prognosis","volume":"15","author":"Baranova","year":"2022","journal-title":"J. Med. Life"},{"key":"10.1016\/j.tranon.2024.102140_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-020-01016-8","article-title":"Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple\u2002negative\u2002breast\u2002cancer cells","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"NPJ Breast. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0007","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2024.102140_bib0008","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.3390\/cancers13246209","article-title":"The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer","volume":"13","author":"He","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2024.102140_bib0009","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","article-title":"DOT1L is a novel cancer stem cell target for triple-negative breast cancer","volume":"28","author":"Kurani","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41419-019-1512-6","article-title":"Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy","volume":"10","author":"He","year":"2019","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2024.102140_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5619472","article-title":"Stemness in cancer: stem cells, cancer stem cells, and their microenvironment","volume":"2017","author":"Aponte","year":"2017","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.tranon.2024.102140_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/209748","article-title":"The role of cancer stem cells in the organ tropism of breast cancer metastasis: a mechanistic balance between the \u201cseed\u201d and the \u201csoil\u201d?","volume":"2012","author":"Chu","year":"2012","journal-title":"Int. J. Breast. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0013","first-page":"1","article-title":"Organotropism: new insights into molecular mechanisms of breast cancer metastasis","volume":"2","author":"Chen","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0014","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2024.102140_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2024.102140_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6602970","article-title":"Mutation of the PIK3CA oncogene in human cancers","volume":"94","author":"Karakas","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0019","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2024.102140_bib0020","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/cells9091970","article-title":"Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy","volume":"9","author":"Yoshida","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2024.102140_bib0021","first-page":"4529","article-title":"Research progress on the PI3K\/AKT signaling pathway in gynecological cancer (Review)","volume":"19","author":"Shi","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.tranon.2024.102140_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.tranon.2024.102140_bib0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tranon.2024.102140_bib0024","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2024.102140_bib0028","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0026","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2024.102140_bib0027","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2024.102140_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2024.102140_bib0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2024.102140_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121708","article-title":"Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation","volume":"324","author":"de Godoy","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.tranon.2024.102140_bib0032","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/jpm12111793","article-title":"PIK3CAMutations in breast cancer subtypes other than HR-positive\/HER2-negative","volume":"12","author":"Ascione","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tranon.2024.102140_bib0033","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2024.102140_bib0034","first-page":"1580","article-title":"Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the ion torrent sequencing platform","volume":"42","author":"Fan","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2024.102140_bib0035","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4161\/cc.8.9.8255","article-title":"PIK3CA mutations in human solid tumors","volume":"8","author":"Ligresti","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tranon.2024.102140_bib0036","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2024.102140_bib0037","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2024.102140_bib0038","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0039","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-021-06242-3","article-title":"Spectrum of PIK3CA\/AKT mutations across molecular subtypes of triple-negative breast cancer","volume":"187","author":"Kumar","year":"2021","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2024.102140_bib0041","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","article-title":"Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data","volume":"36","author":"Zardavas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0042","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","article-title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial","volume":"33","author":"Liu","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901858","article-title":"Co-delivery of paclitaxel and interleukin-12 regulating tumor microenvironment for cancer immunochemotherapy","volume":"9","author":"Hu","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.tranon.2024.102140_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35821","article-title":"Epigenetic profiles of triple-negative breast cancers of African American and white females","volume":"6","author":"Ensenyat-Mendez","year":"2023","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.tranon.2024.102140_bib0044","first-page":"5451","article-title":"Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells","volume":"60","author":"SSW","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0045","first-page":"1087","article-title":"Inhibition of phosphatidylinositol 3\u2019-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models","volume":"62","author":"Hu","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0049","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/1541-7786.MCR-17-0108","article-title":"p120-Catenin downregulation and PIK3CA mutations cooperate to induce invasion through MMP1 in HNSCC","volume":"15","author":"Kidacki","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu Rev. Cell Dev. Biol."},{"key":"10.1016\/j.tranon.2024.102140_bib0051","doi-asserted-by":"crossref","first-page":"8868","DOI":"10.1158\/0008-5472.CAN-09-1968","article-title":"Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase","volume":"69","author":"Pang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0052","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202200077","article-title":"Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations","volume":"22","author":"Saraswat","year":"2022","journal-title":"Proteomics"},{"key":"10.1016\/j.tranon.2024.102140_bib0053","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0054","first-page":"554","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science (1979)"},{"key":"10.1016\/j.tranon.2024.102140_bib0055","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tranon.2024.102140_bib0056","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1038\/s41598-022-16405-x","article-title":"Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells","volume":"12","author":"Hong","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2024.102140_bib0057","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/j.clbc.2020.02.002","article-title":"Targeting PIK3CA alterations in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: new therapeutic approaches and practical considerations","volume":"20","author":"Schwartzberg","year":"2020","journal-title":"Clin. Breast. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0058","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1535-7163.MCT-19-0261","article-title":"Transgelin 2 promotes paclitaxel resistance, migration, and invasion of breast cancer by directly interacting with PTEN and activating PI3K\/Akt\/GSK-3\u03b2 pathway","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2024.102140_bib0047","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2024.102140_bib0059","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.semcancer.2017.11.017","article-title":"Re-evaluating the role of FOXOs in cancer","volume":"50","author":"Hornsveld","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.tranon.2024.102140_bib0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/cancers9100134","article-title":"The epithelial-to-mesenchymal transition in breast cancer: focus on basal-like carcinomas","volume":"9","author":"Fedele","year":"2017","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2024.102140_bib0061","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0062","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0063","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0064","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2013.10.007","article-title":"Primary and secondary distant metastatic breast cancer: two sides of the same coin","volume":"23","author":"G\u00fcth","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.tranon.2024.102140_bib0065","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/bcr3071","article-title":"Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases","volume":"13","author":"Adamo","year":"2011","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0066","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.1038\/ncomms13796","article-title":"GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment","volume":"7","author":"Song","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2024.102140_bib0067","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/ol.2020.12331","article-title":"Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K\/Akt\/MDM2\/p53 and PI3K\/Akt\/mTOR signaling pathways","volume":"21","author":"Liu","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2024.102140_bib0068","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/bj3460561","article-title":"The PI3K-PDK1 connection: more than just a road to PKB","volume":"3","author":"Vanhaesebroeck","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.tranon.2024.102140_bib0069","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011189","article-title":"PI3K-PKB\/Akt pathway","volume":"4","author":"Hemmings","year":"2012","journal-title":"Cold. Spring. Harb. Perspect. Biol."},{"key":"10.1016\/j.tranon.2024.102140_bib0070","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00216-011-5257-z","article-title":"Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives","volume":"401","author":"Huang","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.tranon.2024.102140_bib0071","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fonc.2014.00252","article-title":"The PTEN\/PI3K\/AKT pathway in vivo, cancer mouse models","volume":"4","author":"Carnero","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0072","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.3390\/cancers14215306","article-title":"The predictive and prognostic role of RAS\u2013RAF\u2013MEK\u2013ERK pathway alterations in breast cancer: revision of the literature and comparison with the analysis of cancer genomic datasets","volume":"14","author":"Rocca","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2024.102140_bib0073","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0074","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/excr.1999.4701","article-title":"Signaling by distinct classes of phosphoinositide 3-kinases","volume":"253","author":"Vanhaesebroeck","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0077","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2024.102140_bib0079","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13058-019-1176-2","article-title":"Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes","volume":"21","author":"Sobral-Leite","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.536072","article-title":"PIK3CA is regulated by CUX1, promotes cell growth and metastasis in bladder cancer via activating epithelial-mesenchymal transition","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105224","article-title":"PI3K signaling through a biochemical systems lens","volume":"299","author":"Madsen","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2024.102140_bib0094","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2024.102140_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1108242","article-title":"The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+\/PIK3CA mutant breast cancer","volume":"13","author":"Cataldo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0096","doi-asserted-by":"crossref","first-page":"GS2","DOI":"10.1158\/1538-7445.SABCS17-GS2-07","article-title":"Abstract GS2-07: MANTA - a randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer","volume":"78","author":"Schmid","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0097","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","article-title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","volume":"32","author":"Dent","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0098","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0099","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1535-7163.MCT-13-0159","article-title":"Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models","volume":"12","author":"Xu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2024.102140_bib0101","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.3390\/ijms22073464","article-title":"PI3K Inhibitors in cancer: clinical implications and adverse effects","volume":"22","author":"Mishra","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2024.102140_bib0102","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1-selective inhibition with Alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12907-015-0020-6","article-title":"Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer","volume":"15","author":"Arsenic","year":"2015","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.tranon.2024.102140_bib0104","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2024.102140_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10549-011-1518-y","article-title":"Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes","volume":"132","author":"Boyault","year":"2012","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2024.102140_bib0106","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/cancers15030703","article-title":"Current state and future challenges for PI3K inhibitors in cancer therapy","volume":"15","author":"Sirico","year":"2023","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2024.102140_bib0107","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.annonc.2022.03.185","article-title":"166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from BEGONIA, a phase Ib\/II study","volume":"33","author":"Schmid","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0108","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1016\/j.annonc.2020.08.457","article-title":"355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant\/hormone receptor-positive\/HER2-negative locally advanced or metastatic breast cancer (HR+\/HER2\u2013 LA\/MBC)","volume":"31","author":"Turner","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0109","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/0008-5472.CAN-14-0092","article-title":"Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer","volume":"74","author":"Jiang","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0110","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","article-title":"PIK3CA mutation associates with improved outcome in breast cancer","volume":"15","author":"Kalinsky","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2024.102140_bib0111","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0082","doi-asserted-by":"crossref","first-page":"54082","DOI":"10.18632\/oncotarget.10789","article-title":"CXCL12\/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner","volume":"8","author":"Abdelouahab","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2024.102140_bib0083","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41423-023-01013-0","article-title":"The chemokine monocyte chemoattractant protein-1\/CCL2 is a promoter of breast cancer metastasis","volume":"20","author":"Yoshimura","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.tranon.2024.102140_bib0084","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3892\/or.2017.5453","article-title":"CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K\/Akt\/NF-\u03baB signaling pathway","volume":"37","author":"Shen","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2024.102140_bib0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","article-title":"CCL5\/CCR5 axis in human diseases and related treatments","volume":"9","author":"Zeng","year":"2022","journal-title":"Genes. Dis."},{"key":"10.1016\/j.tranon.2024.102140_bib0086","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1074\/mcp.M115.049783","article-title":"Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)\/extracellular signal-regulated kinase (ERK) paracrine signaling axis in basal-like breast cancer","volume":"14","author":"Young","year":"2015","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.tranon.2024.102140_bib0087","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41698-017-0017-y","article-title":"Revisiting the IGF-1R as a breast cancer target","volume":"1","author":"Ekyalongo","year":"2017","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.tranon.2024.102140_bib0088","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-015-0291-7","article-title":"The role of the insulin-like growth factor-1 system in breast cancer","volume":"14","author":"Christopoulos","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2024.102140_bib0089","doi-asserted-by":"crossref","first-page":"e30801","DOI":"10.1371\/journal.pone.0030801","article-title":"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features","volume":"7","author":"Byron","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2024.102140_bib0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/1535-7163.MCT-18-0710","article-title":"Cooperative effect of oncogenic MET and PIK3CA in an HGF-dominant environment in breast cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2024.102140_bib0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.tranon.2024.102140_bib0076","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.humpath.2008.06.004","article-title":"High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer","volume":"39","author":"Ghosh","year":"2008","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tranon.2024.102140_bib0091","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41467-020-16496-y","article-title":"Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation","volume":"11","author":"Martinez-Corral","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2024.102140_bib0092","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12964-023-01225-x","article-title":"PI3K\/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells","volume":"21","author":"Maharati","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.tranon.2024.102140_bib0093","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","article-title":"PIK3CA-mutations in breast cancer","volume":"196","author":"Reinhardt","year":"2022","journal-title":"Breast. Cancer Res. Treat."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:33:01Z","timestamp":1739323981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":109,"alternative-id":["S1936523324002675"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102140","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102140"}}